154 related articles for article (PubMed ID: 38653401)
1. Stimulating intestinal GIP release reduces food intake and body weight in mice.
Lewis JE; Nuzzaci D; James-Okoro PP; Montaner M; O'Flaherty E; Darwish T; Hayashi M; Liberles SD; Hornigold D; Naylor J; Baker D; Gribble FM; Reimann F
Mol Metab; 2024 Jun; 84():101945. PubMed ID: 38653401
[TBL] [Abstract][Full Text] [Related]
2. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
[TBL] [Abstract][Full Text] [Related]
3. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
4. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Zhang Q; Delessa CT; Augustin R; Bakhti M; Colldén G; Drucker DJ; Feuchtinger A; Caceres CG; Grandl G; Harger A; Herzig S; Hofmann S; Holleman CL; Jastroch M; Keipert S; Kleinert M; Knerr PJ; Kulaj K; Legutko B; Lickert H; Liu X; Luippold G; Lutter D; Malogajski E; Medina MT; Mowery SA; Blutke A; Perez-Tilve D; Salinno C; Sehrer L; DiMarchi RD; Tschöp MH; Stemmer K; Finan B; Wolfrum C; Müller TD
Cell Metab; 2021 Apr; 33(4):833-844.e5. PubMed ID: 33571454
[TBL] [Abstract][Full Text] [Related]
5. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.
Liskiewicz A; Khalil A; Liskiewicz D; Novikoff A; Grandl G; Maity-Kumar G; Gutgesell RM; Bakhti M; Bastidas-Ponce A; Czarnecki O; Makris K; Lickert H; Feuchtinger A; Tost M; Coupland C; Ständer L; Akindehin S; Prakash S; Abrar F; Castelino RL; He Y; Knerr PJ; Yang B; Hogendorf WFJ; Zhang S; Hofmann SM; Finan B; DiMarchi RD; Tschöp MH; Douros JD; Müller TD
Nat Metab; 2023 Dec; 5(12):2075-2085. PubMed ID: 37946085
[TBL] [Abstract][Full Text] [Related]
6. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
Campbell JE
Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves.
Mayer F; Gunawan AL; Tso P; Aponte GW
Am J Physiol Gastrointest Liver Physiol; 2020 Jul; 319(1):G23-G35. PubMed ID: 32421358
[TBL] [Abstract][Full Text] [Related]
8. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
[TBL] [Abstract][Full Text] [Related]
9. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological antagonism of the incretin system protects against diet-induced obesity.
Svendsen B; Capozzi ME; Nui J; Hannou SA; Finan B; Naylor J; Ravn P; D'Alessio DA; Campbell JE
Mol Metab; 2020 Feb; 32():44-55. PubMed ID: 32029229
[TBL] [Abstract][Full Text] [Related]
11. An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.
Ma T; Lu W; Wang Y; Qian P; Tian H; Gao X; Yao W
Eur J Pharmacol; 2022 Jan; 914():174635. PubMed ID: 34800466
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
[TBL] [Abstract][Full Text] [Related]
13. Chronic high-fat feeding increases GIP and GLP-1 secretion without altering body weight.
Wang F; Yoder SM; Yang Q; Kohan AB; Kindel TL; Wang J; Tso P
Am J Physiol Gastrointest Liver Physiol; 2015 Nov; 309(10):G807-15. PubMed ID: 26336929
[TBL] [Abstract][Full Text] [Related]
14. Selective release of gastrointestinal hormones induced by an orally active GPR39 agonist.
Grunddal KV; Diep TA; Petersen N; Tough IR; Skov LJ; Liu L; Buijink JA; Mende F; Jin C; Jepsen SL; Sørensen LME; Achiam MP; Strandby RB; Bach A; Hartmann B; Frimurer TM; Hjorth SA; Bouvier M; Cox H; Holst B
Mol Metab; 2021 Jul; 49():101207. PubMed ID: 33711555
[TBL] [Abstract][Full Text] [Related]
15. Intestinal Gpr17 deficiency improves glucose metabolism by promoting GLP-1 secretion.
Yan S; Conley JM; Reilly AM; Stull ND; Abhyankar SD; Ericsson AC; Kono T; Molosh AI; Kubal CA; Evans-Molina C; Ren H
Cell Rep; 2022 Jan; 38(1):110179. PubMed ID: 34986353
[TBL] [Abstract][Full Text] [Related]
16. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
17. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
18. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
[TBL] [Abstract][Full Text] [Related]
19. Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.
West JA; Tsakmaki A; Ghosh SS; Parkes DG; Grønlund RV; Pedersen PJ; Maggs D; Rajagopalan H; Bewick GA
PLoS One; 2021; 16(3):e0249239. PubMed ID: 33788878
[TBL] [Abstract][Full Text] [Related]
20. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors.
Spielman LJ; Gibson DL; Klegeris A
Eur J Cell Biol; 2017 May; 96(3):240-253. PubMed ID: 28336086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]